184 related articles for article (PubMed ID: 27915435)
1. Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.
Yao S; Zhang Y; Tang L; Roh JM; Laurent CA; Hong CC; Hahn T; Lo JC; Ambrosone CB; Kushi LH; Kwan ML
Breast Cancer Res Treat; 2017 Feb; 161(3):501-513. PubMed ID: 27915435
[TBL] [Abstract][Full Text] [Related]
2. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Yao S; Laurent CA; Roh JM; Lo J; Tang L; Hahn T; Ambrosone CB; Kushi LH; Kwan ML
Breast Cancer Res Treat; 2020 Feb; 180(1):187-195. PubMed ID: 31912328
[TBL] [Abstract][Full Text] [Related]
3. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.
Becker T; Lipscombe L; Narod S; Simmons C; Anderson GM; Rochon PA
J Am Geriatr Soc; 2012 Sep; 60(9):1761-7. PubMed ID: 22985145
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
[TBL] [Abstract][Full Text] [Related]
7. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
8. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.
Stratton J; Hu X; Soulos PR; Davidoff AJ; Pusztai L; Gross CP; Mougalian SS
J Oncol Pract; 2017 May; 13(5):e505-e515. PubMed ID: 28267392
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients.
Monroy-Cisneros K; Esparza-Romero J; Valencia ME; Guevara-Torres AG; Méndez-Estrada RO; Anduro-Corona I; Astiazarán-García H
BMC Cancer; 2016 Nov; 16(1):860. PubMed ID: 27821086
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
11. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
Schmidt N; Jacob L; Coleman R; Kostev K; Hadji P
Breast Cancer Res Treat; 2016 Jan; 155(1):151-7. PubMed ID: 26687384
[TBL] [Abstract][Full Text] [Related]
12. Low bone density in breast cancer survivors in Korea: prevalence, risk factors and associations with health-related quality of life.
Kim SH; Cho YU; Kim SJ; Lee JE; Kim JH
Eur J Oncol Nurs; 2013 Apr; 17(2):196-203. PubMed ID: 22898655
[TBL] [Abstract][Full Text] [Related]
13. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
14. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
15. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
18. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.
Koopal C; Janssen-Heijnen ML; van de Wouw AJ; van den Bergh JP
Breast; 2015 Apr; 24(2):153-8. PubMed ID: 25618224
[TBL] [Abstract][Full Text] [Related]
19. Skeletal health in postmenopausal survivors of early breast cancer.
Mackey JR; Joy AA
Int J Cancer; 2005 May; 114(6):1010-5. PubMed ID: 15645435
[TBL] [Abstract][Full Text] [Related]
20. Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy.
Knobf MT; Jeon S; Smith B; Harris L; Kerstetter J; Thompson AS; Insogna K
Breast Cancer Res Treat; 2016 Feb; 155(3):491-500. PubMed ID: 26850265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
